IL158285A0 - Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-base assay for determination of immune responses against oxidized low density lipoprotein - Google Patents

Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-base assay for determination of immune responses against oxidized low density lipoprotein

Info

Publication number
IL158285A0
IL158285A0 IL15828502A IL15828502A IL158285A0 IL 158285 A0 IL158285 A0 IL 158285A0 IL 15828502 A IL15828502 A IL 15828502A IL 15828502 A IL15828502 A IL 15828502A IL 158285 A0 IL158285 A0 IL 158285A0
Authority
IL
Israel
Prior art keywords
peptide
atherosclerosis
determination
development
treatment
Prior art date
Application number
IL15828502A
Other languages
English (en)
Original Assignee
Forskarpatent I Syd Ab Cedars
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0101232A external-priority patent/SE0101232D0/xx
Application filed by Forskarpatent I Syd Ab Cedars filed Critical Forskarpatent I Syd Ab Cedars
Publication of IL158285A0 publication Critical patent/IL158285A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
IL15828502A 2001-04-05 2002-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-base assay for determination of immune responses against oxidized low density lipoprotein IL158285A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0101232A SE0101232D0 (sv) 2001-04-05 2001-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based elisa for determination of immune responses against oxidized low density liprotein
SE0103754A SE0103754L (sv) 2001-04-05 2001-11-09 Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
PCT/SE2002/000679 WO2002080954A1 (en) 2001-04-05 2002-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein

Publications (1)

Publication Number Publication Date
IL158285A0 true IL158285A0 (en) 2004-05-12

Family

ID=26655437

Family Applications (4)

Application Number Title Priority Date Filing Date
IL15828502A IL158285A0 (en) 2001-04-05 2002-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-base assay for determination of immune responses against oxidized low density lipoprotein
IL158285A IL158285A (en) 2001-04-05 2003-10-07 Peptides for preparing medicament for immuno- therapy of atherosclerosis and development of peptide-base assay for determination of immune responses against oxidized low density lipoprotein
IL188286A IL188286A0 (en) 2001-04-05 2007-12-20 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
IL195356A IL195356A0 (en) 2001-04-05 2008-11-18 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL158285A IL158285A (en) 2001-04-05 2003-10-07 Peptides for preparing medicament for immuno- therapy of atherosclerosis and development of peptide-base assay for determination of immune responses against oxidized low density lipoprotein
IL188286A IL188286A0 (en) 2001-04-05 2007-12-20 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
IL195356A IL195356A0 (en) 2001-04-05 2008-11-18 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein

Country Status (18)

Country Link
EP (42) EP2289931A1 (es)
JP (6) JP2004529143A (es)
CN (4) CN1505525B (es)
AT (2) ATE415423T1 (es)
AU (1) AU2002246484B8 (es)
BR (1) BR0208685A (es)
CA (3) CA2606839C (es)
CY (1) CY1108817T1 (es)
DE (1) DE60230029D1 (es)
DK (3) DK2006301T3 (es)
EE (2) EE200700052A (es)
ES (2) ES2546293T3 (es)
IL (4) IL158285A0 (es)
PL (4) PL215401B1 (es)
PT (1) PT1383526E (es)
RU (1) RU2296582C2 (es)
SE (1) SE0103754L (es)
WO (1) WO2002080954A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
CN1283313C (zh) 2001-09-28 2006-11-08 埃斯佩里安医疗公司 α螺旋状载脂蛋白或HDL关联蛋白在制备局部给药预防和治疗再狭窄的药物中的用途
AU2003267905B2 (en) * 2002-10-04 2009-02-05 Biolnvent International Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302422D0 (sv) * 2003-09-11 2003-09-11 Forskarpatent I Syd Ab Peptide-based immunization therapy for treatment of atherosclerosis
SE0400683D0 (sv) * 2004-03-19 2004-03-19 Forskarpatent I Syd Ab Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis
EP1732383A4 (en) 2004-04-06 2007-05-02 Cedars Sinai Medical Center PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH VIRUS VECTORS ASSOCIATED WITH RECOMBINANT ADENOVIRUS CODING APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO
DK1735349T3 (da) 2004-04-15 2010-12-06 Athera Biotechnologies Ab Fremgangsmåde til fastlæggelse af risikoen for iskæmisk cardiovaskulær sygdom under anvendelse af phosphorylcholinkonjugater
EP1676602A1 (en) * 2005-01-04 2006-07-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Continuous administration of epitopes derived from protein present in atherosclerotic plaque for the treatment of atherosclerosis
GB0517878D0 (en) 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
MX2009006744A (es) * 2006-12-22 2009-06-30 Abbott Lab Panel de padecimiento cardiovascular autoinmune y metodos de utilizacion del mismo.
WO2008104194A1 (en) * 2007-02-28 2008-09-04 Bioinvent International Ab Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques
EP2137162B1 (en) 2007-03-15 2018-08-01 Novartis AG Organic compounds and their uses
JP6039879B2 (ja) * 2007-11-05 2016-12-07 ノルディック・ビオサイエンス・エー／エスＮｏｒｄｉｃ Ｂｉｏｓｃｉｅｎｃｅ Ａ／Ｓ Ｃｖｄリスク評価のための生化学マーカー
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
WO2010018870A1 (ja) * 2008-08-15 2010-02-18 藤倉化成株式会社 動脈硬化診断用ポリペプチドマーカー、及び該マーカー等を用いる動脈硬化の検出方法、並びに動脈硬化診断用キット
WO2011060329A1 (en) 2009-11-14 2011-05-19 Kuang-Yuh Chyu Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
US8506964B2 (en) * 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
US20130142760A1 (en) 2010-08-18 2013-06-06 Cedars-Sinai Medical Center Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
US9205139B2 (en) 2010-11-12 2015-12-08 Cardiovax, Llc Immunomodulatory methods and systems for treatment and/or prevention of aneurysms
EP2637689A2 (en) * 2010-11-12 2013-09-18 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
JP2014516914A (ja) * 2010-11-12 2014-07-17 シーダース シナイ メディカル センター Ａｐｏｂ１００の免疫原性断片を含む免疫調節組成物、方法及びシステム
LT2742068T (lt) 2011-08-09 2019-07-10 Athera Biotechnologies Ab Nauji antikūnai prieš fosforilcholiną
CN103906532B (zh) 2011-08-09 2018-01-26 阿瑟拉生物技术公司 结合磷酰胆碱（pc）和/或pc结合物的抗体
RU2495048C1 (ru) * 2012-04-18 2013-10-10 Андрей Валентинович Исаев Пептид, обладающий антиатеросклеротическим действием и композиция для профилактики и лечения атеросклероза сосудов
RU2662973C2 (ru) 2012-11-06 2018-07-31 Лез Опито Юниверситер Де Женев Пептидомиметики
CN103520713B (zh) * 2013-10-16 2015-10-28 西北农林科技大学 一种ApoB100酵母重组疫苗及其制备方法和应用
CN103860470A (zh) * 2014-03-05 2014-06-18 贵州中泰生物科技有限公司 一种口服高密度脂蛋白脂质体的制备方法
CN105315364B (zh) * 2014-06-17 2018-09-18 广州文瑞生物科技有限公司 胶原蛋白vi疫苗预防动脉粥样硬化
WO2016187250A1 (en) * 2015-05-19 2016-11-24 La Jolla Institute For Allergy And Immunology Human apob100 epitopes, methods and uses for modulating inflammatory responses, and treating adverse cardiovascular events, disease and atherosclerosis
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CN108478817B (zh) * 2018-03-16 2020-10-27 北京大学 一种动脉粥样硬化检测试剂及其制备方法
JP7357646B2 (ja) 2018-05-29 2023-10-06 アブセントラ，エルエルシー 乾癬の治療のための組成物及び方法
CA3129373A1 (en) 2018-05-29 2019-12-05 Abcentra, Llc Compositions and methods for treatment of rheumatoid arthritis and accelerated atherosclerosis

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970144A (en) 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US5972890A (en) 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
WO1993018067A1 (en) * 1992-03-06 1993-09-16 Abbott Laboratories Immunocapture assay for direct quantitation of specific lipoprotein cholesterol levels
WO1994000592A1 (en) * 1992-06-26 1994-01-06 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
KR0185334B1 (ko) 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
GB9609702D0 (en) * 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
GB9620153D0 (en) * 1996-09-27 1996-11-13 Univ Strathclyde Non-naturally occurring lipoprotein particle
GB9705831D0 (en) * 1997-03-20 1997-05-07 Univ Leicester Oxidised ldl
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US6156315A (en) * 1997-10-10 2000-12-05 The Trustees Of Columbia University In The City Of New York Method for inhibiting the binding of low density lipoprotein to blood vessel matrix
EP0911344B1 (en) * 1997-10-15 2004-03-03 Fujirebio Inc. Anti-Apo-B-48 monoclonal antibody, hybridoma, and methods of use
AU760794B2 (en) * 1998-03-10 2003-05-22 Regents Of The University Of California, The Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
WO2000002920A1 (en) * 1998-07-13 2000-01-20 University Of Otago Inhibition of lipoprotein formation
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
WO2001032070A2 (en) * 1999-10-26 2001-05-10 The Regents Of The University Of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
AU2001233114A1 (en) * 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
DE60103137T2 (de) * 2000-03-03 2005-05-25 Glaxosmithkline Biologicals S.A. Impstoff zur behandlung von atherosclerosis
SE0000855D0 (sv) * 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
GB0017641D0 (en) * 2000-07-18 2000-09-06 Medigene Oy Peptides and their use
EP1186299A1 (en) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
EP1592445A4 (en) * 2000-10-25 2007-01-10 Vincent Agnello METHOD FOR INHIBITING HEPATITIS C VIRUS (HCV) INFECTION AND OTHER FLAVIRIDAE / I FAMILY VIRUSES, AND OTHER BLOODY-VIRUSES COMPLEXING WITH LOW OR VERY LOW DENSITY LIPOPROTEIN DENSITY, BY PREVENTING VIRAL ENTRY IN A CELL
AU2002241603A1 (en) * 2000-11-10 2002-06-03 University Of Utah Research Foundation Carrier system for specific artery wall gene delivery
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
WO2002092630A1 (en) * 2001-05-15 2002-11-21 Japan Immunoresearch Laboratories Co., Ltd. High density lipoprotein-reactive peptides
JP2005504025A (ja) * 2001-07-20 2005-02-10 アイトゲネシシェ テクニシェ ホッヒシュル チューリッヒ（エーテーハーツェット） スルフォネート化またはスルフェート化アミノ酸から誘導された生物学的薬剤の使用法と組成物

Also Published As

Publication number Publication date
JP2011068654A (ja) 2011-04-07
EP2289934B1 (en) 2013-11-13
EP1918300A3 (en) 2009-06-17
JP2013144687A (ja) 2013-07-25
EP2147928A2 (en) 2010-01-27
BR0208685A (pt) 2004-03-30
CY1108817T1 (el) 2014-04-09
IL158285A (en) 2009-12-24
JP5613890B2 (ja) 2014-10-29
EP2006301B1 (en) 2011-05-25
EP2305707A1 (en) 2011-04-06
EP2289933A1 (en) 2011-03-02
DK2006301T3 (da) 2011-09-12
WO2002080954A1 (en) 2002-10-17
CN103122031A (zh) 2013-05-29
EP2289921A1 (en) 2011-03-02
EP2289927A1 (en) 2011-03-02
CA2606839A1 (en) 2002-10-17
EP2289925A1 (en) 2011-03-02
EP2289912A1 (en) 2011-03-02
EP2289919A1 (en) 2011-03-02
EP2289928A1 (en) 2011-03-02
EP2295459A1 (en) 2011-03-16
IL195356A0 (en) 2009-08-03
EP2289929A1 (en) 2011-03-02
EP2289935A1 (en) 2011-03-02
EP2305708A1 (en) 2011-04-06
CA2443223A1 (en) 2002-10-17
EP2147680A2 (en) 2010-01-27
PT1383526E (pt) 2009-02-27
EP2289931A1 (en) 2011-03-02
EP2147930A2 (en) 2010-01-27
EP2295457A1 (en) 2011-03-16
DE60230029D1 (de) 2009-01-08
EP1918300A2 (en) 2008-05-07
EP2295462A1 (en) 2011-03-16
CN1505525A (zh) 2004-06-16
CN103122031B (zh) 2015-07-22
EE200300487A (et) 2004-02-16
EP2289920A1 (en) 2011-03-02
EP2295460A1 (en) 2011-03-16
EP2289916A1 (en) 2011-03-02
EP2295458A1 (en) 2011-03-16
EP2305706A1 (en) 2011-04-06
EP2289923A1 (en) 2011-03-02
SE0103754D0 (sv) 2001-11-09
CA2443223C (en) 2013-11-26
EP2289932A1 (en) 2011-03-02
SE0103754L (sv) 2002-10-06
EP2289922A1 (en) 2011-03-02
EP2289934A1 (en) 2011-03-02
EP2147930A3 (en) 2010-04-14
JP5300819B2 (ja) 2013-09-25
EP2006301A1 (en) 2008-12-24
AU2002246484A1 (en) 2002-10-21
EP1383526B1 (en) 2008-11-26
ES2546293T3 (es) 2015-09-22
EP2147680A3 (en) 2010-04-14
AU2002246484B8 (en) 2007-06-14
CN101486766A (zh) 2009-07-22
EP2295464B1 (en) 2015-06-03
RU2296582C2 (ru) 2007-04-10
CA2827167A1 (en) 2002-10-17
ATE415423T1 (de) 2008-12-15
IL188286A0 (en) 2008-03-20
JP5300820B2 (ja) 2013-09-25
EP2147929A2 (en) 2010-01-27
JP2009191078A (ja) 2009-08-27
DK1383526T3 (da) 2009-03-30
CA2606839C (en) 2015-06-09
EP2295464A1 (en) 2011-03-16
EP2147929A3 (en) 2010-04-14
EP2295460B1 (en) 2015-06-03
PL215401B1 (pl) 2013-12-31
PL217858B1 (pl) 2014-08-29
AU2002246484B2 (en) 2007-04-19
EP2147928A3 (en) 2010-04-14
EP1383526A1 (en) 2004-01-28
EP2289924A1 (en) 2011-03-02
ES2317999T3 (es) 2009-05-01
EP2289926A1 (en) 2011-03-02
EP2295463A1 (en) 2011-03-16
EP2289914A1 (en) 2011-03-02
JP5270456B2 (ja) 2013-08-21
PL367301A1 (en) 2005-02-21
RU2003132443A (ru) 2005-02-27
CN101284874B (zh) 2012-10-03
CN1505525B (zh) 2012-11-07
EP2295461A1 (en) 2011-03-16
EE200700052A (et) 2008-08-15
JP2008169215A (ja) 2008-07-24
ATE510851T1 (de) 2011-06-15
EP2289917A1 (en) 2011-03-02
JP2011063598A (ja) 2011-03-31
EP2289930A1 (en) 2011-03-02
EP2289913A1 (en) 2011-03-02
JP2004529143A (ja) 2004-09-24
EP2289918A1 (en) 2011-03-02
PL400308A1 (pl) 2012-12-17
EP2289915A1 (en) 2011-03-02
CN101284874A (zh) 2008-10-15
DK2295464T3 (en) 2015-08-17

Similar Documents

Publication Publication Date Title
IL188286A0 (en) Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
AT500379B8 (de) Tau-proteine
ID26645A (id) Protein-protein utant yang memiliki respons alergenik yang lebih rendah pada manusia dan metode-metode untuk menyusun, mengidentifikasi dan menghasilkan protein-protein semacam itu
PT700445E (pt) Proteinas de stress e suas utilizacoes
NO922744D0 (no) Peptidblanding og fremgangsmaate ved paavisning av antistoffer htlv-iii
HK1087018A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
Tian et al. Effect of Rothia mucilaginosa enzymes on gliadin (gluten) structure, deamidation, and immunogenic epitopes relevant to celiac disease
KR970027305A (ko) 인간 혈장 아포지단백질(apolipoprotein) B-100에 결합하는 생쥐 항체를 암호하는 cDNA
DE69635582D1 (de) Diagnostika und behandlungen von peridontalen erkrankungen
IL160533A0 (en) Methods of screening molecules that are used to prevent cardiovascular diseases
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
KR100310413B1 (ko) 인간의자연형lgM항체
BRPI0216033B8 (pt) "terapia de imunização à base de peptídio para tratamento de arteriosclerose"
DE60336214D1 (de) Methoden zur analyse von antikörperdisulfidisomere
WO2002023202A3 (en) Method to identify antibody targets based on mass spectrometry (maldi-tof)
DK1275638T3 (da) Kombinationspræparat til behandling af immunologiske sygdomme
SE0202959D0 (sv) Peptide-Base passive immunization therapy for treatment of atherosclerosis